BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250312T080000
DTEND;TZID=America/New_York:20260312T170000
DTSTAMP:20260423T051337
CREATED:20250620T061332Z
LAST-MODIFIED:20250620T062541Z
UID:10000002-1741766400-1773334800@mednetus.net
SUMMARY:Ocular Surface Disease: Pathophysiology\, Evaluation\, Management with Topical Agents\, and Neuromodulation
DESCRIPTION:CME | 1.25 Credits \n\n\n\n\n\n\nWebcast \nTime to Complete: 75 minutes \nReleased: March 12\, 2025 \nExpires: March 12\, 2026 \nMaximum Credits:\n1.25 / AMA PRA Category 1 CreditsTM \n\n\n\n\n\n\n\n\n\nStart Activity\n\n\n\nProgram Description \nThis webcast provides an update on the ocular surface diseases. Cornea and conjunctiva\, lids\, exocrine glands and their innervation form an integrated entity\, which regulates the production of tear fluid.1 Stable tear fluid is essential in nourishing and protecting the ocular surface from external threats\, such as pollution\, desiccation\, injuries\, allergens and pathogens. Maintaining and protecting the transparent\, avascular cornea is particularly important for good visual acuity. Thus\, an integral part of the functioning of the ocular surface relies on the tear fluid. \nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surfaces diseases. \nCommercial Supporter \nThis activity is supported by an educational grant from Dompé US Inc. \n\n\n\n\n\n\n\n\nLearning Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology\, risk factor\, and evaluation of ocular surface disease\nInterpret data on artificial tear formulations and neuromodulation in managing ocular surface disease\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAccredited Providers \nThis activity is provided by Amedco and MedNet. \n       \nJoint Accreditation Statement \nIn support of improving patient care\, Amedco and MedNet have planned and implemented this activity. Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. MedNet serves as the content and logistic provider for this activity. Amedco designates this activity for 1.25 AMA PRA Category 1 CreditsTM \nPhysicians Credit Designation \nAmedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nAdditional Credit Information \nPhysician Assistants\nAAPA accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors\, and allows reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours. \nThrough an agreement between the American Medical Association (AMA) and the European Union of Medical Specialists\, physicians and healthcare providers may convert CME/CE PRA Category 1 CreditsTM to an equivalent number of European CME Credits® (ECMECs®). The UEMS-EACCME® has recognition agreements with the AMA for live events and e-learning materials. \nFaculty \n \nSarah B. Sunshine\, MD\nAssistant Professor\, Ophthalmology\nUniversity of Maryland and Greenebaum Comprehensive Cancer\nBaltimore\, MD \nDr. Sunshine discloses the following:\nConsultant: Astra Zeneca\, GSK\nResearch Support: Incyte (IIT)\, Eversight\, NIH \n\nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nACCME – Amedco\nPhone Number: 651-789-3730\nE-Mail: Sheryl@amedcoemail.com \nPrivacy Policy \nmyCME privacy policy
URL:https://mednetus.net/event/ocular-surface-disease-pathophysiology-evaluation-management-with-topical-agents-and-neuromodulation/
CATEGORIES:Webcast
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/032rt0jpt6u4-OSD800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250416T080000
DTEND;TZID=America/New_York:20260416T170000
DTSTAMP:20260423T051337
CREATED:20250620T070737Z
LAST-MODIFIED:20250620T070737Z
UID:10000012-1744790400-1776358800@mednetus.net
SUMMARY:Dry Eye Disease: Current and Emerging Novel Tear Stimulating Therapies for Improved Outcomes
DESCRIPTION:CME | 1.25 Credits \n\n\n\nWebcast \nTime to Complete: 75 minutes \nReleased: April 16\, 2025 \nExpires: April 16\, 2026 \nMaximum Credits:\n1.25 / AMA PRA Category 1 CreditsTM \nResume Activity \nProgram Description \nThis enduring webcast program explores the latest advancements in tear-stimulating therapies. Dive into current treatments and discover novel approaches poised to revolutionize patient outcomes. This activity promises to provide invaluable insights and practical strategies for healthcare professionals dedicated to improving eye health. \nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with dry eye disease \nCommercial Supporter \nSupported by an unrestricted educational grant from Oyster Point. \n\nLearning Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology and factors contributing to DED\, such as preservatives in topicals\, refractive or cataract surgery\, menopause\, and autoimmune diseases\nAssess real-world evidence surrounding available and new tear-stimulating therapies to improve patient outcomes of individuals with DED\n\nAccredited Providers \nThis activity is provided by Amedco and MedNet. \n   \nJoint Accreditation Statement \nIn support of improving patient care\, Amedco and MedNet have planned and implemented this activity. Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. MedNet serves as the content and logistic provider for this activity. Amedco designates this activity for 1.25 AMA PRA Category 1 CreditsTM \nPhysicians Credit Designation \nAmedco designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nAdditional Credit Information \nNote to Physician Assistants\nAAPA accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours. \nNote to Nurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors\, and allows reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours. \nThrough an agreement between the American Medical Association (AMA) and the European Union of Medical Specialists\, physicians and healthcare providers may convert CME/CE PRA Category 1 CreditsTM to an equivalent number of European CME Credits® (ECMECs®). The UEMS-EACCME® has recognition agreements with the AMA for live events and e-learning materials. \nFaculty \n> \nNeal Guymon\, OD\nOptometrist\nSummit EyeCare\nIdaho Falls\, ID \nDr. Guymon discloses the following:\nContent Creator: TearRestore Inc. and Danelli Ocular Creations; Affiliate for Danelli Ocular Creations \n \nEric D. Donnefeld\, MD\nClinical Professor of Ophthalmology\nNew York University Langone Medical Center\nOphthalmic Consultants of Long Island\nNew York\, NY \nDr. Donnefeld discloses the following:\nSpeaker: Allegro\, Abbvie\, Alcon\, AVTRMed\, Aurion\, Bausch & Lomb\, CorneaGen\, Covalent\, CRST\, Crystilex\, BVI\, Blephex\, ELT Sight\, EyePoint Pharma\, Foresight\, Glaukos\, Horizon Surgical Systems\, Inversa\, Johnson & Johnson\, Kala\, Katena\, Lacripen\, LayerBio\, LensGen\, Mati Pharmaceuticals\, Melt Pharmaceuticals\, MDBackline\, MOA\, Nordic Pharma\, Novabay\, Ocular Innovations\, Oculis\, Omega Ophthalmics\, Ocuhub\, PRN\, Rayner\, ReTear\, Singular\, Strathspey Crown\, Surface\, Tarsus\, Tearscience\, Tenpoint Pharma\, Versant Ventures\, Visionary Venture\, and Zeiss \nInstructions \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nACCME – Amedco\nPhone Number: 651-789-3730\nE-Mail: justin@amedcoemail.com \nPrivacy Policy \nmyCME privacy policy
URL:https://mednetus.net/event/dry-eye-disease-current-and-emerging-novel-tear-stimulating-therapies-for-improved-outcomes-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/wsi48i3zt0wr-Enduring800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250719T080000
DTEND;TZID=America/New_York:20250719T170000
DTSTAMP:20260423T051337
CREATED:20250620T065419Z
LAST-MODIFIED:20250620T065419Z
UID:10000011-1752912000-1752944400@mednetus.net
SUMMARY:New Paradigms in the Management of Hereditary Transthyretin Amyloidosis Mixed Phenotype (ATTRv): ATTRv-CM and ATTRv-PN
DESCRIPTION:July 19\, 2025 \nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nSaturday\, July 19\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 CreditsTM\n1.25 / ANCC Contact Hours \nCost \nFree \n\nProgram Description \nWebinar Registration – ZoomTake Me to the Event Registration \nThis program will provide up-to-date\, evidence-based information for diagnosing and managing ATTR-CM and ATTR-PN patients. The activity will focus on: \n\nATTR-CM and ATTR-PN – Frequency and characteristics of ATTR-CM and ATTR-PN\nDiagnosis of ATTR-CM\n\nNuclear scintigraphy (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\nCardiovascular magnetic resonance (CMR)\nEchocardiography\nMagnetic resonance imaging (MRI)\nWestern blot assay\n\n\nDiagnosis of ATTR-PN\n\nScreening laboratory tests include blood glucose evaluations\, serum free light chain (FLC) serum B12 with metabolites\, and serum and urine immunofixation electrophoresis.\nTTR gene sequencing\, looking for TTR gene amyloidogenic variants\, and tools for detecting amyloid deposits.\nHistological documentation of amyloid in diagnosing ATTR.\nCongo red staining with apple green birefringence under polarized light represents the pathognomonic appearance of amyloid.\nSural nerve biopsy for confirming ATTRv-PN\, with a sensitivity of up to 86%.\nTarget organ biopsy offers the highest diagnostic yield; less invasive methods like abdominal fat aspiration or salivary gland biopsy are viable alternatives.\n\n\nTreatment of ATTR-CM and ATTR-PN- Novel treatment options for ATTR-CM and ATTR-PN\n\nTetramer stabilizers – Acoramidis\, Tafamidis\n\nAcoramidis\, FDA accepted the New Drug Application (NDA) on February 5\, 2024\, as an oral treatment for ATTR-CM.\nTafamidis is FDA-approved for treating wild-type ATTR (ATTRwt) and hereditary ATTR (ATTRv) cardiomyopathy.\n\n\nAntisense oligonucleotides – Eplontersen\, Inotersen\n\nEplontersen FDA accepted Fast track designation on Feb 8\, 2024\, for ATTR-CM\, and in December 2023\, eplontersen was approved for the treatment of ATTR-PN\nInotersen was FDA-approved for the treatment of ATTR-PN\n\n\nSmall interfering RNAs – Patisiran\, Vutrisiran\n\nPatisiran is approved for the treatment of ATTR-PN\nVutrisiran is approved for both the ATTR-CM and ATTR-PN\n\n\nNonsteroidal anti-inflammatory drug – Diflunisal\nInvestigational therapies include a TTR stabilizer\, AG10; 2 antifibril agents\, PRX004 and doxycycline/tauroursodeoxycholic acid; and 2 gene silencers\, vutrisiran and AKCEA-TTR-LRx; and clinical trials are ongoing.\n\n\n\nAgenda \n• Discuss the diagnosis and novel treatment options for ATTR-CM – Michelle Kittleson\, MD\, PhD \n• Discuss the diagnosis and novel treatment options for ATTR-PN – Chafic Karam\, MD \nIntended Audience \nCardiologists\, neurologists\, geneticists\, radiologists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses who diagnose and treat patients with hereditary transthyretin amyloidosis (ATTRv;v for variant)\, ATTR-CM and ATTR-PN. \nCommercial Supporter \nSupported by a restricted educational grant from Alnylam U.S.\, Inc. \nLearning Objectives \n\nSummarize the characteristics\, related disabilities\, comorbidities\, and variable disease presentations and course of hereditary transthyretin amyloidosis mixed phenotype\nAppraise nuclear scintigraphy’s role (including Tc99m PYP\, Tc-99m DPD\, and Tc-99m HDMP)\, genetic testing in diagnosing patients with suspected ATTR-CM and ATTR-PN\nIdentify novel treatment options for ATTR-CM and ATTR-PN with tetramer stabilizers\, antisense oligonucleotides\, and small interfering RNAs\nImplement interdisciplinary care for patients with ATTR-CM and ATTR-PN\, incorporating primary and specialty care\, supportive ancillary services\, and shared decision-making.\n\nAccredited Providers \nJointly Accredited by Haymarket Medical Education and MedNet \n   \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Haymarket Medical Education and MedNet. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Haymarket Medical Education Joint Accreditation #JA4008232. \nPhysicians (ACCME) Credit Designation \nHaymarket Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses \nThis activity is awarded 1.25 contact hours (based on 60 minutes per contact hour). \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nMichelle M. Kittleson\, M.D.\, Ph.D.\nDirector of Education in Heart Failure and Transplantation\nProfessor of Medicine\nSmidt Heart Institute\, Cedars-Sinai\nLos Angeles\, CA \nDr. Kittleson has no relevant financial relationships with ineligible companies to disclose. \n \nChafic Karam\, MD\nProfessor of Clinical Neurology\nChief\, Neuromuscular Division\nDirector\, Neuromuscular Fellowship\nDepartment of Neurology\nUniversity of Pennsylvania\nPhiladelphia\, PA \nDr. Karam reports the following relevant financial relationships with ineligible companies to disclose:\nConsultant: Alnylam\, AstraZeneca\, Novo Nordisk\, Alexion\, Corino\, and Pfizer\nResearch Support: Ionis \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like Zoom may be necessary. \nCost \nThere are no fees for participating and receiving CME and CE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-paradigms-in-the-management-of-hereditary-transthyretin-amyloidosis-mixed-phenotype-attrv-attrv-cm-and-attrv-pn/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/n81qh2gf0iyb-ATTRvLive800x450.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251115T082500
DTEND;TZID=America/New_York:20251115T123000
DTSTAMP:20260423T051337
CREATED:20250815T162214Z
LAST-MODIFIED:20251103T191354Z
UID:10000021-1763195100-1763209800@mednetus.net
SUMMARY:Changing Landscape of Management in Eye Diseases: Glaucoma\, Ocular Surface Disease\, Neurotrophic Keratitis\, Cataract Surgery\, and Vitreoretinal Surgery
DESCRIPTION:
URL:https://mednetus.net/event/changing-landscape-of-management-in-eye-diseases-glaucoma-ocular-surface-disease-neurotrophic-keratitis-cataract-surgery-and-vitreoretinal-surgery/
LOCATION:Zoom Live Webinar\, United States
CATEGORIES:Live Program
END:VEVENT
END:VCALENDAR